- Subject is an infant born to a mother who was exposed to study drug on a tanezumab
- The infant's mother (who was the tanezumab clinical study participant) must review,
agree and sign an informed consent document explaining the details of the perinatal
and post natal follow up. Where local regulations mandate, the male parent would also
review and sign the informed consent.
- Parents or legal guardian must be willing and able to comply with scheduled visits and
- There are no exclusion criteria for participating in this study.